Kimberly Gentile net worth and biography

Kimberly Gentile Biography and Net Worth

SVP of Biohaven

Ms. Gentile has 30 years of experience in the pharmaceutical industry in all phases of clinical research from Phase 1 through Phase 4, predominantly in the areas of psychiatry and neurology. She has deep, hands-on experience in most key operational aspects of drug development, having held positions at small biotechnology companies, contract research organizations, investigative sites as well as small and large pharmaceutical companies. Prior to joining Biohaven in 2014, Ms. Gentile spent 14 years in the Clinical Operations group at Bristol-Myers Squibb where she was responsible for operational oversight of large-scale global programs in the areas of psychiatry and neurology, including the management of complex global programs in Anxiety Disorders, Treatment Resistant Depression and Alzheimer’s Disease. She has a proven track record of successfully managing complex and challenging drug development programs within set timelines and budgets.

What is Kimberly Gentile's net worth?: The estimated net worth of Kimberly Gentile is at least $984,060.14 as of October 8th, 2020. Ms. Gentile owns 27,139 shares of Biohaven stock worth more than $984,060 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Gentile may own. Additionally, Ms. Gentile receives an annual salary of $858,650.00 as SVP at Biohaven. Learn More about Kimberly Gentile's net worth.
How old is Kimberly Gentile?: Ms. Gentile is currently 58 years old. There are 5 older executives and no younger executives at Biohaven. The oldest executive at Biohaven is Mr. Matthew Buten, Chief Financial Officer, who is 63 years old. Learn More on Kimberly Gentile's age.
What is Kimberly Gentile's salary?: As the SVP of Biohaven Ltd., Ms. Gentile earns $858,650.00 per year. There are 3 executives that earn more than Ms. Gentile. The highest earning executive at Biohaven is Dr. Vladimir Coric M.D., Chairman & CEO, who commands a salary of $1,960,000.00 per year. Learn More on Kimberly Gentile's salary.
How do I contact Kimberly Gentile?: The corporate mailing address for Ms. Gentile and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Kimberly Gentile's contact information.
Has Kimberly Gentile been buying or selling shares of Biohaven?: Kimberly Gentile has not been actively trading shares of Biohaven over the course of the past ninety days. Most recently, Kimberly Gentile sold 23,500 shares of the business's stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $76.34, for a transaction totalling $1,793,990.00. Following the completion of the sale, the senior vice president now directly owns 27,139 shares of the company's stock, valued at $2,071,791.26. Learn More on Kimberly Gentile's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

Kimberly Gentile Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2020	Sell	23,500	$76.34	$1,793,990.00	27,139
6/17/2020	Sell	24,000	$70.20	$1,684,800.00	27,639
6/8/2020	Sell	600	$70.05	$42,030.00	4,239
11/20/2019	Sell	3,935	$53.03	$208,673.05	3,935
6/15/2018	Sell	12,500	$40.02	$500,250.00	12,500
3/1/2018	Sell	5,000	$32.87	$164,350.00
2/1/2018	Sell	5,000	$32.78	$163,900.00	5,000
1/2/2018	Sell	5,000	$27.60	$138,000.00	5,000
12/1/2017	Sell	5,000	$21.99	$109,950.00
11/1/2017	Sell	5,000	$29.28	$146,400.00	5,000

Kimberly Gentile Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $36.26

$34.46

$36.95

50 Day Range

MA: $47.21

$35.34

$53.69

2 Week Range

Now: $36.26

$26.80

$62.21

Volume

3,229,003 shs

Average Volume

1,130,245 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Kimberly Gentile Biography and Net Worth

What is Kimberly Gentile's net worth?

How old is Kimberly Gentile?

What is Kimberly Gentile's salary?

How do I contact Kimberly Gentile?

Has Kimberly Gentile been buying or selling shares of Biohaven?

Who are Biohaven's active insiders?

Are insiders buying or selling shares of Biohaven?